GSK files Votrient in ovarian cancer in the EU
This article was originally published in Scrip
GlaxoSmithKline has filed its targeted anticancer Votrient (pazopanib) in the EU for a third indication, the maintenance treatment of women with Stage II-IV ovarian, fallopian tube or primary peritoneal cancer who have not progressed after receiving first-line chemotherapy. This marks the first filing for this use, but the company adds that it is working on submissions in other countries worldwide.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.